PortalPublikationenIgD Subtype But Not IgM or Non-Secretory Is a Prognostic Mar...

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study

Standard

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study. / Lawless, Sarah; Sbianchi, Giulia; Morris, Curly; Iacobelli, Simona; Bosman, Paul; Blaise, Didier; Reményi, Péter; Byrne, J L; Mayer, Jiri; Apperley, Jane; Lund, Johan; Kobbe, Guido; Schaap, Nicolaas; Isaksson, Cecilia; Lenhoff, Stig; Basak, Grzegorz; Touzeau, Cyrille; Wilson, Keith M O; González Muñiz, Soledad; Scheid, Christof; Browne, Paul; Anagnostopoulos, Achilles; Rambaldi, Alessandro; Jantunen, Esa; Kröger, Nicolaus; Schönland, Stefan; Yakoub-Agha, Ibrahim; Garderet, Laurent.

in: CL LYMPH MYELOM LEUK, Jahrgang 21, Nr. 10, 10.2021, S. 686-693.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Lawless, S, Sbianchi, G, Morris, C, Iacobelli, S, Bosman, P, Blaise, D, Reményi, P, Byrne, JL, Mayer, J, Apperley, J, Lund, J, Kobbe, G, Schaap, N, Isaksson, C, Lenhoff, S, Basak, G, Touzeau, C, Wilson, KMO, González Muñiz, S, Scheid, C, Browne, P, Anagnostopoulos, A, Rambaldi, A, Jantunen, E, Kröger, N, Schönland, S, Yakoub-Agha, I & Garderet, L 2021, 'IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study', CL LYMPH MYELOM LEUK, Jg. 21, Nr. 10, S. 686-693. https://doi.org/10.1016/j.clml.2021.05.012

APA

Lawless, S., Sbianchi, G., Morris, C., Iacobelli, S., Bosman, P., Blaise, D., Reményi, P., Byrne, J. L., Mayer, J., Apperley, J., Lund, J., Kobbe, G., Schaap, N., Isaksson, C., Lenhoff, S., Basak, G., Touzeau, C., Wilson, K. M. O., González Muñiz, S., ... Garderet, L. (2021). IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study. CL LYMPH MYELOM LEUK, 21(10), 686-693. https://doi.org/10.1016/j.clml.2021.05.012

Vancouver

Lawless S, Sbianchi G, Morris C, Iacobelli S, Bosman P, Blaise D et al. IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study. CL LYMPH MYELOM LEUK. 2021 Okt;21(10):686-693. https://doi.org/10.1016/j.clml.2021.05.012

Bibtex

@article{1f09705bfe934540bf2b8209787aefe4,
title = "IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study",
abstract = "BACKGROUND: The Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study has provided an opportunity to evaluate the real-world outcomes of patients with myeloma. The aim of this study was to compare the outcome according to the different subtypes of myeloma using CALM data.PATIENTS: This study compared overall survival (OS), progression-free survival (PFS), and complete remission (CR) and the impact of novel versus non-novel drug containing induction regimens prior to autologous hematopoietic cell transplantation (HCT) of 2802 patients with {"}usual{"} and {"}rare{"} myelomas.RESULTS: Our data suggest that IgM and non-secretory myeloma have superior PFS and OS compared with IgD myeloma and outcomes comparable to those for usual myeloma. Patients who received novel agent induction had higher rates of CR prior to transplant. Non-novel induction regimens were associated with inferior PFS but no difference in OS. Although not the primary focus of this study, we show that poor mobilization status is associated with reduced PFS and OS, but these differences disappear in multivariate analysis suggesting that poor mobilization status is a surrogate for other indicators of poor prognosis.CONCLUSION: We confirm that IgD myeloma is associated with the worst prognosis and inferior outcomes compared with the other isotypes.",
author = "Sarah Lawless and Giulia Sbianchi and Curly Morris and Simona Iacobelli and Paul Bosman and Didier Blaise and P{\'e}ter Rem{\'e}nyi and Byrne, {J L} and Jiri Mayer and Jane Apperley and Johan Lund and Guido Kobbe and Nicolaas Schaap and Cecilia Isaksson and Stig Lenhoff and Grzegorz Basak and Cyrille Touzeau and Wilson, {Keith M O} and {Gonz{\'a}lez Mu{\~n}iz}, Soledad and Christof Scheid and Paul Browne and Achilles Anagnostopoulos and Alessandro Rambaldi and Esa Jantunen and Nicolaus Kr{\"o}ger and Stefan Sch{\"o}nland and Ibrahim Yakoub-Agha and Laurent Garderet",
note = "Copyright {\textcopyright} 2021 Elsevier Inc. All rights reserved.",
year = "2021",
month = oct,
doi = "10.1016/j.clml.2021.05.012",
language = "English",
volume = "21",
pages = "686--693",
journal = "CL LYMPH MYELOM LEUK",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "10",

}

RIS

TY - JOUR

T1 - IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study

AU - Lawless, Sarah

AU - Sbianchi, Giulia

AU - Morris, Curly

AU - Iacobelli, Simona

AU - Bosman, Paul

AU - Blaise, Didier

AU - Reményi, Péter

AU - Byrne, J L

AU - Mayer, Jiri

AU - Apperley, Jane

AU - Lund, Johan

AU - Kobbe, Guido

AU - Schaap, Nicolaas

AU - Isaksson, Cecilia

AU - Lenhoff, Stig

AU - Basak, Grzegorz

AU - Touzeau, Cyrille

AU - Wilson, Keith M O

AU - González Muñiz, Soledad

AU - Scheid, Christof

AU - Browne, Paul

AU - Anagnostopoulos, Achilles

AU - Rambaldi, Alessandro

AU - Jantunen, Esa

AU - Kröger, Nicolaus

AU - Schönland, Stefan

AU - Yakoub-Agha, Ibrahim

AU - Garderet, Laurent

N1 - Copyright © 2021 Elsevier Inc. All rights reserved.

PY - 2021/10

Y1 - 2021/10

N2 - BACKGROUND: The Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study has provided an opportunity to evaluate the real-world outcomes of patients with myeloma. The aim of this study was to compare the outcome according to the different subtypes of myeloma using CALM data.PATIENTS: This study compared overall survival (OS), progression-free survival (PFS), and complete remission (CR) and the impact of novel versus non-novel drug containing induction regimens prior to autologous hematopoietic cell transplantation (HCT) of 2802 patients with "usual" and "rare" myelomas.RESULTS: Our data suggest that IgM and non-secretory myeloma have superior PFS and OS compared with IgD myeloma and outcomes comparable to those for usual myeloma. Patients who received novel agent induction had higher rates of CR prior to transplant. Non-novel induction regimens were associated with inferior PFS but no difference in OS. Although not the primary focus of this study, we show that poor mobilization status is associated with reduced PFS and OS, but these differences disappear in multivariate analysis suggesting that poor mobilization status is a surrogate for other indicators of poor prognosis.CONCLUSION: We confirm that IgD myeloma is associated with the worst prognosis and inferior outcomes compared with the other isotypes.

AB - BACKGROUND: The Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study has provided an opportunity to evaluate the real-world outcomes of patients with myeloma. The aim of this study was to compare the outcome according to the different subtypes of myeloma using CALM data.PATIENTS: This study compared overall survival (OS), progression-free survival (PFS), and complete remission (CR) and the impact of novel versus non-novel drug containing induction regimens prior to autologous hematopoietic cell transplantation (HCT) of 2802 patients with "usual" and "rare" myelomas.RESULTS: Our data suggest that IgM and non-secretory myeloma have superior PFS and OS compared with IgD myeloma and outcomes comparable to those for usual myeloma. Patients who received novel agent induction had higher rates of CR prior to transplant. Non-novel induction regimens were associated with inferior PFS but no difference in OS. Although not the primary focus of this study, we show that poor mobilization status is associated with reduced PFS and OS, but these differences disappear in multivariate analysis suggesting that poor mobilization status is a surrogate for other indicators of poor prognosis.CONCLUSION: We confirm that IgD myeloma is associated with the worst prognosis and inferior outcomes compared with the other isotypes.

U2 - 10.1016/j.clml.2021.05.012

DO - 10.1016/j.clml.2021.05.012

M3 - SCORING: Journal article

C2 - 34158265

VL - 21

SP - 686

EP - 693

JO - CL LYMPH MYELOM LEUK

JF - CL LYMPH MYELOM LEUK

SN - 2152-2650

IS - 10

ER -